Towards personalized medicine in sepsis: Quest for Shangri-La?

Critical Care

Volumn 17, Issue 1, 2013, Pages

  Sen, Ayan ^a   Yende, Sachin ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CORTICOSTEROID; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADAPTIVE IMMUNITY; ARTICLE; CADAVER; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE DURATION; DISEASE SEVERITY; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE STATUS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INTENSIVE CARE UNIT; LUNG CANCER; LUNG PARENCHYMA; MULTIPLE ORGAN FAILURE; NUTRITIONAL STATUS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SPLEEN CELL; SPLENECTOMY; TIME OF DEATH; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; SECRETION (PROCESS);

CYTOKINES; FEMALE; HUMANS; IMMUNE TOLERANCE; MALE; MULTIPLE ORGAN FAILURE; SEPSIS;

EID: 84873525075     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12485     Document Type: Article

References (18)

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
2. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 2001, 16:83-96. 10.1097/00024382-200116020-00001, 11508871.
3. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8:776-787. 10.1038/nri2402, 2786961, 18802444.
4. Wang TS, Deng JC. Molecular and cellular aspects of sepsis-induced immunosuppression. J Mol Med (Berl) 2008, 86:495-506. 10.1007/s00109-007-0300-4, 18259721.
5. Fisher CJ, Agosti JM, O pal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996, 334:1697-1702. 10.1056/NEJM199606273342603, 8637514.
6. Remick DG. Cytokine therape utics for the treatment of sepsis: why has nothing worked?. Curr Pharm Des 2003, 9:75-82. 10.2174/1381612033392567, 12570677.
7. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150. 10.1056/NEJMra021333, 12519925.
8. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009, 101:36-47.
9. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996, 24:1125-1128. 10.1097/00003246-199607000-00010, 8674323.
10. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang ML, Santo Hayes TK, Corey L, Boeckh M. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008, 300:413-422. 2774501, 18647984.
11. Luyt CE, Combes A, Deback C, Aubriot-Lorton MH, Nieszkowska A, Trouillet JL, Capron F, Agut H, Gibert C, Chastre J. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007, 175:935-942. 10.1164/rccm.200609-1322OC, 17234903.
12. Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coopersmith CM, Hotchkiss RS. Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun 2010, 78:1582-1592. 10.1128/IAI.01213-09, 2849407, 20100863.
13. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009, 15:496-497. 10.1038/nm0509-496, 19424209.
14. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605. 10.1001/jama.2011.1829, 3361243, 22187279.
15. Opal SM. Immunologic alter ations and the pathogenesis of organ failure in the ICU. Semin Respir Crit Care Med 2011, 32:569-580. 10.1055/s-0031-1287865, 21989693.
16. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008, 14:64-78. 2078557, 18026569.
17. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk HD. Granulocytemacrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009, 180:640-648. 10.1164/rccm.200903-0363OC, 19590022.
18. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454. 10.1056/NEJMoa1200690, 3544539, 22658127.